In Section C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will get treatment till condition progression or even the individuals are not able to tolerate the study drugs. then promote H3K27Ac at this location. Chromatin hyperacetylation could enhance the accessibility https://abbv-744clinicaltrialphas15723.dailyhitblog.com/37522669/5-tips-about-clinical-effectiveness-of-abbv-744-in-aml-patients-you-can-use-today